Merck Kgaa Unsp ADR (MKGAY) 39.1500 $MKGAY
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)
M2 - Fri Apr 10, 4:04AM CDT
Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US, today announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib). This agreement showcases the alliance's commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab*-based treatment regimens in the future.
PFE: 35.44 (+0.41)
Global Cell Analysis Market Report 2015 - Forecast to 2020
M2 - Wed Apr 08, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8px4d/cell_analysis) has announced the addition of the "Cell Analysis Global Market - Forecast To 2020" report to their offering. Cell analysis plays a major role in gene identification, protein identification, transcription analysis and epigenomics at cellular level. It proves to be an ultra-sensitive device to elucidate specific molecular processes and pathways and reveal the nature of cell heterogenecity. Hospitals, academic institutions, government bodies, as well as pharmaceutical and biotechnology firms are increasing their focus on application of cell analysis as a modern emerging tool in research, drug discovery and diagnosis. The cell analysis techniques global market is segmented into molecular approaches, image-based approaches and others. The molecular approaches include the PCR, NGS and Microfluidics, cell isolation & separation techniques performed at cells genomic level, where as the image-based approaches include microscopes, FISH, FRAP, tracking, high content screening (HCS), cytometry techniques etc. The cell analysis products market is mainly segmented into consumables and instruments. The consumables include reagents, assay plates and microplates where as the instrument segment comprises of microscopes, flow cytometers, spectrophotometer, quantitative polymerase chain reaction (QPCR), microfluidic devices, cell counters, high content screening (HCS) systems and cell microarrays. By application, the market is segmented into by processes, by feild and by therapeutics. By processes is segmented into Cellular processes, Signal transduction pathways, Circulating tumor cells, Single cell analysis, Epigentic target analysis, Subpopulation Characterization, Drug and candidate screening. By field is further segmented into forensic Science, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. By therapeutics is further segmented into cancer research, infectious disease diagnosis, genetic testing, immunology, others. By end-users, the market is segmented into Hospitals, Academic and Research Institutes, Contract Research Organizations (CROs), Pharmaceuticals and Biotechnology Companies, Cell Banks, Diagnostic Laboratories and others. By geography, the market is segmented into North America, Europe, Asia Pacific and Rest of World. North America holds the largest market share, followed by Europe and Asia. The APAC regions tend to be an emerging market with an opportunity for growth and are likely to be a destination of investment for new investors in the cell analysis market. Drug discovery services outsourcing and government funding for novel screening technologies has resulted in growth of Asian markets. The cell analysis market is expected to grow at a rate of 9.6% during the forecast period. The major factor influencing the growth is enhanced precision of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing incidence of cancer, increasing government investments, funds and grants, availability of reagents and cell analysis instruments are driving the growth of the market. However, the major market restraints include high capital investments and shortage of skilled labour for high content screening procedure. The biggest opportunities for this market is the emerging APAC market, high content screening services provided by contract research organizations, automation in cancer research for its early diagnosis and reduction of cost in the cancer treatment. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Cell Analysis Global Market, Techniques 5 Global Cell Analysis Products Market 6 Global Cell Analysis Applications Market 7 Cell Analysis Global Market, By End-Users 8 Regional Market Analysis 9 Company Developments 10 Major Player Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/v8...l_analysis
A: 43.55 (+1.06), SIAL: 138.45 (-0.09), DHR: 84.98 (-0.48)
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI(R) (crizotinib)
Business Wire - Tue Apr 07, 7:00AM CDT
--In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck KGaA, Darmstadt, Germany
PFE: 35.44 (+0.41)
Gastroesophageal (GE) Junction Carcinomas Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 6:30AM CDT
The report "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. The gastroesophageal junction lies at the top of the stomach in the upper abdomen. Conditions that afflict the gastroesophageal junction include hiatal hernia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/gastroesopha...eport.html .
MACK: 12.17 (+0.17), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), BMY: 64.64 (+1.18), EXEL: 3.04 (+0.03)
EMD Serono Launches 11th Edition of The EMD Serono Specialty Digest(TM) at Annual Meeting of The Academy of Managed Care Pharmacy
PR Newswire - Mon Apr 06, 9:42AM CDT
EMD Serono, the U.S. biopharmaceuticals subsidiary of Merck KGaA, Darmstadt, Germany, today announced the launch of the 11th edition of the EMD Serono Specialty Digest(TM) at the 27th Annual Meeting of The Academy of Managed Care Pharmacy (AMCP) in San Diego, CA. The Digest is an educational resource that provides market data on health plans' management of specialty pharmaceuticals in 2014 and identifies common trends occurring across plans. The Digest is available to those who request a copy at http://www.specialtydigest.emdserono.com.
EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology
PR Newswire - Wed Apr 01, 8:30AM CDT
EMD Serono, the U.S. biopharmaceuticals subsidiary of Merck KGaA, Darmstadt, Germany, announced today the appointment of Frederick E. Munschauer to Vice President of Medical Affairs, Neurology and Immunology. In this capacity, he will lead the medical affairs activities for clinical, commercial and business development projects and collaborations for Rebif® (interferon beta-1a) as well as the company's Immunology and Neurology pipeline.
Movado and CBRE Group are big market movers
AP - Tue Mar 31, 3:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
CTRX: 59.61 (+0.30), FBHS: 46.14 (+0.15), DUK: 77.84 (+0.83), CHTR: 191.81 (+0.88), UNH: 119.00 (+0.45), KRFT: 89.27 (-0.13), ASPX: 100.58 (+0.10), CCT.TO: 75.01 (+0.37), OFIX: 37.32 (-0.39), HPTX: 45.79 (-0.01), TCK: 13.75 (-0.21), DYN: 31.31 (+0.46), MOV: 31.37 (-0.25), JCI: 50.09 (-0.46)
Why Shares Intrexon Corp are Skyrocketing Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 30, 11:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Intrexon Corp surged higher...
ZIOP: 10.13 (+0.43), XON: 42.89 (+0.87)
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
GlobeNewswire - Mon Mar 30, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM.
ZIOP: 10.13 (+0.43), MRK: 57.25 (-0.18), XON: 42.89 (+0.87)
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
PR Newswire - Mon Mar 30, 7:00AM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
MRK: 57.25 (-0.18), XON: 42.89 (+0.87)
The Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany, and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy
PR Newswire - Mon Mar 30, 7:00AM CDT
The biopharmaceutical business of Merck KGaA, Darmstadt, Germany, and Intrexon Corporation (NYSE:XON), today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances the comprehensive, science-driven strategy of Merck KGaA, Darmstadt, Germany, to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
XON: 42.89 (+0.87)
Is This Tiny Biotech Still a Buy at All-Time Highs?
Maxx Chatsko, The Motley Fool - Motley Fool - Fri Mar 27, 6:58AM CDT
Does a soaring stock price mean investors should stay away or jump on the bandwagon? Well, it depends. Investors need to consider a multitude of factors, including financial metrics, growth rates, market opportunities, management style, competitive...
RGEN: 30.50 (+0.15), GE: 28.51 (+2.78), MRK: 57.25 (-0.18)
PharmaPoint: Global Colorectal Cancer Drug Forecast and Market Analysis to 2023
M2 - Mon Mar 23, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/blc46f/pharmapoint) has announced the addition of the "PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023" report to their offering. China's Colorectal Cancer Treatment Market Value to Exceed $1 Billion by 2023 This report provides annualized colorectal cancer therapeutics market revenue, cost of therapy, and treatment usage patterns across eight major markets, namely the US, France, Germany, Italy, Spain, UK, Japan and China, from 2013 and forecast to 2023. Key topics covered include pipeline analysis, strategic competitor assessment, unmet needs, remaining commercial opportunities, and current and future players. The Chinese treatment market for colorectal cancer (CRC) will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 15.1%, according to research and consulting firm The authors. The report states that this increase, which will make China the third largest global market for CRC treatment behind the US and Japan, will be driven by increasing disease incidence in urban populations, rising numbers of people covered by private health insurance and improved access to branded biologicals. However, Fenix Leung, DPhil, The authors's Analyst covering Oncology and Hematology, says that growth will be stymied by the patent expiration of Avastin, the leading drug in the Chinese CRC treatment market, and the slower uptake of pipeline therapies. Leung explains: There is often a delay in new drug launches in China relative to the US, Europe and Japan, due to an extended approval process by the China Food and Drug Administration (CFDA). For drugs that have not undergone clinical trials in Chinese patients prior to their application submission, the CFDA can require additional safety studies to be conducted in China before accepting a registration application. As nintedanib, Cyramza, and Imprime PGG are examples of pipeline products that have not undergone clinical trials in China, we do not expect them to launch in this market during the forecast period. Despite this, the report predicts the market entry of four additional drugs by 2023. These include Amgen/Takeda's Vectibix, Bayer's Stivarga, Sanofi's Zaltrap, and Taiho Pharmaceutical's Lonsurf. Leung continues: These agents will garner combined revenues of $334 million in 2023, representing 32% of the Chinese CRC treatment market. Stivarga is expected to be the clear market leader of these drugs, with peak-year sales of $291 million expected in 2023. This will follow its label extension as an adjuvant treatment for CRC patients with resected liver metastases and prior chemotherapy neoadjuvant/adjuvant treatment, the analyst concludes. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Clinical Staging 3.3 Symptoms 4 Epidemiology 4.1 Disease Background 4.2 Risk Factors and Comorbidities 4.3 Global Trends 4.3.1 8MM, Incidence Trends 4.3.2 8MM, Five-Year Relative Survival 4.3.3 8MM, Screening Programs for CRC 4.4 Forecast Methodology 4.4.1 Sources Used 4.4.2 Sources Not Used 4.4.3 Forecast Assumptions and Methods 4.5 Epidemiological Forecast of CRC (2013-2023) 4.5.1 Diagnosed Incident Cases of CRC 4.5.2 Age-Specific Diagnosed Incident Cases of CRC 4.5.3 Sex-Specific Diagnosed Incident Cases of CRC 4.5.4 Age-Standardized Incidence 4.5.5 Cancer Stage at Diagnosis 4.5.6 Diagnosed Five-Year Prevalent Cases of CRC 4.5.7 KRAS Status among Diagnosed Five-Year Prevalent Cases of CRC 4.6 Discussion 4.6.1 Epidemiological Forecast Insight 4.6.2 Limitations of the Analysis 4.6.3 Strengths of the Analysis 5 Disease Management 5.1 Diagnosis and Treatment Overview 5.1.1 Screening and Diagnosis 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 5.1.3 Clinical Practice 6 Competitive Assessment 6.1 Overview 6.2 Product Profiles Major Brands 6.2.1 Avastin (Bevacizumab) 6.2.2 Erbitux (Cetuximab) 6.2.3 Vectibix (Panitumumab) 6.2.4 Stivarga (Regorafenib) 6.2.5 Zaltrap (Ziv-Aflibrcept) 6.2.6 Lonsurf (TAS-102) 6.2.7 TS-1 (Tegafur, Gimeracil, Oteracil) 6.2.8 Xeloda (Capecitabine) 7 Unmet Need and Opportunity 7.1 Overview 7.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients 7.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients 7.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 7.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients 8 Pipeline Assessment 8.1 Overview 8.2 Promising Drugs in Clinical Development 8.2.1 Cyramza (Ramucirumab) 8.2.2 Imprime PGG 8.2.3 MGN1703 8.2.4 Nintedanib (BIBF-1120) 8.3 Promising Approaches in Early-Stage Development 8.3.1 Anti-Angiopoietin-2 Inhibitors 8.3.2 Strategies for BRAF Mutation-Positive Disease 8.3.3 Strategies for KRAS-Mutation Positive Disease 8.3.4 Immune Checkpoint Inhibitors 9 Current and Future Players 9.1 Overview 9.2 Trends in Corporate Strategy 9.3 Company Profiles 10 Market Outlook 11 Appendix Companies Mentioned - Roche/Genentech - Sanofi - Eli Lilly and Company - Merck KGaA - Bayer - Taiho Pharmaceutical For more information visit http://www.researchandmarkets.com/research/bl...harmapoint
LLY: 73.92 (+1.56)
Merck: Why Is Sigma-Aldrich's Deal With Roche Positive For Investors?
BB Research - at Seeking Alpha - Thu Mar 19, 2:50PM CDT
SIAL: 138.45 (-0.09)
Atherosclerosis Partnering 2010-2015: Deals and agreements entered into by the world's leading healthcare companies
M2 - Thu Mar 19, 10:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z43mj9/atherosclerosis) has announced the addition of the "Atherosclerosis Partnering 2010-2015" report to their offering. The Atherosclerosis Partnering 2010-2015 provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of atherosclerosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors atherosclerosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This data driven report contains over 35 links to online copies of actual atherosclerosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In Atherosclerosis Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in atherosclerosis partnering Chapter 3 - Average deal terms for atherosclerosis Chapter 4 - Active atherosclerosis dealmakers Chapter 5 - Atherosclerosis dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/z4...osclerosis
JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), BIIB: 425.65 (-0.98), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Arrhythmia Partnering 2010-2015: Deals and agreements entered into by the worlds leading healthcare companies
M2 - Thu Mar 19, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3wj9g/arrhythmia) has announced the addition of the "Arrhythmia Partnering 2010-2015" report to their offering. The Arrhythmia Partnering 2010-2015 provides understanding and access to the arrhythmia partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of arrhythmia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors arrhythmia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This data driven report contains over 35 links to online copies of actual arrhythmia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In Arrhythmia Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in arrhythmia partnering Chapter 3 - Average deal terms for arrhythmia Chapter 4 - Active arrhythmia dealmakers Chapter 5 - Arrhythmia dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/z3wj9g/arrhythmia
JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), BIIB: 425.65 (-0.98), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Coronary Artery Disease Partnering 2010-2015: Deals and agreements entered into by the world's leading healthcare companies
M2 - Thu Mar 19, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kpf4dh/coronary_artery) has announced the addition of the "Coronary Artery Disease Partnering 2010-2015" report to their offering. The Coronary Artery Disease Partnering 2010-2015 provides understanding and access to the coronary artery disease partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of coronary artery disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors coronary artery disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This data driven report contains over 60 links to online copies of actual coronary artery disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In Coronary artery disease Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in coronary artery disease partnering Chapter 3 - Average deal terms for coronary artery disease Chapter 4 - Active coronary artery disease dealmakers Chapter 5 - Coronary artery disease dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/kp...ary_artery
JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), BIIB: 425.65 (-0.98), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Liver Cancer Partnering Deals and Agreements 2010-2015 - Analysis from the World's Leading Healthcare Companies
M2 - Thu Mar 19, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8sxzpx/liver_cancer) has announced the addition of the "Liver Cancer Partnering 2010-2015" report to their offering. The Liver Cancer Partnering 2010-2015 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in Liver cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 livercancer deals and contract documents where available - The leading Liver cancer deals by value since 2010 In Liver Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Liver cancer partnering Chapter 3 - Average deal terms for Liver cancer Chapter 4 - Active Liver cancer dealmakers Chapter 5 - Liver cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/8s...ver_cancer
AGN: 240.22 (+2.88), JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Gastric Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gc9gpc/gastric_cancer) has announced the addition of the "Gastric Cancer Partnering 2010-2015" report to their offering. The Gastric Cancer Partnering 2010-2015 provides understanding and access to the gastric cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of gastric cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gastric cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 40 links to online copies of actual gastric cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in gastric cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 40 gastric cancer deals and contract documents where available - The leading gastric cancer deals by value since 2010 In Gastric Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Gastric cancer partnering Chapter 3 - Average deal terms for Gastric cancer Chapter 4 - Active Gastric cancer dealmakers Chapter 5 - Gastric cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/gc...ric_cancer
AGN: 240.22 (+2.88), JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)
M2 - Fri Apr 10, 4:04AM CDT
Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US, today announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib). This agreement showcases the alliance's commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab*-based treatment regimens in the future.
PFE: 35.44 (+0.41)
Global Cell Analysis Market Report 2015 - Forecast to 2020
M2 - Wed Apr 08, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8px4d/cell_analysis) has announced the addition of the "Cell Analysis Global Market - Forecast To 2020" report to their offering. Cell analysis plays a major role in gene identification, protein identification, transcription analysis and epigenomics at cellular level. It proves to be an ultra-sensitive device to elucidate specific molecular processes and pathways and reveal the nature of cell heterogenecity. Hospitals, academic institutions, government bodies, as well as pharmaceutical and biotechnology firms are increasing their focus on application of cell analysis as a modern emerging tool in research, drug discovery and diagnosis. The cell analysis techniques global market is segmented into molecular approaches, image-based approaches and others. The molecular approaches include the PCR, NGS and Microfluidics, cell isolation & separation techniques performed at cells genomic level, where as the image-based approaches include microscopes, FISH, FRAP, tracking, high content screening (HCS), cytometry techniques etc. The cell analysis products market is mainly segmented into consumables and instruments. The consumables include reagents, assay plates and microplates where as the instrument segment comprises of microscopes, flow cytometers, spectrophotometer, quantitative polymerase chain reaction (QPCR), microfluidic devices, cell counters, high content screening (HCS) systems and cell microarrays. By application, the market is segmented into by processes, by feild and by therapeutics. By processes is segmented into Cellular processes, Signal transduction pathways, Circulating tumor cells, Single cell analysis, Epigentic target analysis, Subpopulation Characterization, Drug and candidate screening. By field is further segmented into forensic Science, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. By therapeutics is further segmented into cancer research, infectious disease diagnosis, genetic testing, immunology, others. By end-users, the market is segmented into Hospitals, Academic and Research Institutes, Contract Research Organizations (CROs), Pharmaceuticals and Biotechnology Companies, Cell Banks, Diagnostic Laboratories and others. By geography, the market is segmented into North America, Europe, Asia Pacific and Rest of World. North America holds the largest market share, followed by Europe and Asia. The APAC regions tend to be an emerging market with an opportunity for growth and are likely to be a destination of investment for new investors in the cell analysis market. Drug discovery services outsourcing and government funding for novel screening technologies has resulted in growth of Asian markets. The cell analysis market is expected to grow at a rate of 9.6% during the forecast period. The major factor influencing the growth is enhanced precision of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing incidence of cancer, increasing government investments, funds and grants, availability of reagents and cell analysis instruments are driving the growth of the market. However, the major market restraints include high capital investments and shortage of skilled labour for high content screening procedure. The biggest opportunities for this market is the emerging APAC market, high content screening services provided by contract research organizations, automation in cancer research for its early diagnosis and reduction of cost in the cancer treatment. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Cell Analysis Global Market, Techniques 5 Global Cell Analysis Products Market 6 Global Cell Analysis Applications Market 7 Cell Analysis Global Market, By End-Users 8 Regional Market Analysis 9 Company Developments 10 Major Player Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/v8...l_analysis
A: 43.55 (+1.06), SIAL: 138.45 (-0.09), DHR: 84.98 (-0.48)
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI(R) (crizotinib)
Business Wire - Tue Apr 07, 7:00AM CDT
--In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck KGaA, Darmstadt, Germany
PFE: 35.44 (+0.41)
Gastroesophageal (GE) Junction Carcinomas Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 6:30AM CDT
The report "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. The gastroesophageal junction lies at the top of the stomach in the upper abdomen. Conditions that afflict the gastroesophageal junction include hiatal hernia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/gastroesopha...eport.html .
MACK: 12.17 (+0.17), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), BMY: 64.64 (+1.18), EXEL: 3.04 (+0.03)
EMD Serono Launches 11th Edition of The EMD Serono Specialty Digest(TM) at Annual Meeting of The Academy of Managed Care Pharmacy
PR Newswire - Mon Apr 06, 9:42AM CDT
EMD Serono, the U.S. biopharmaceuticals subsidiary of Merck KGaA, Darmstadt, Germany, today announced the launch of the 11th edition of the EMD Serono Specialty Digest(TM) at the 27th Annual Meeting of The Academy of Managed Care Pharmacy (AMCP) in San Diego, CA. The Digest is an educational resource that provides market data on health plans' management of specialty pharmaceuticals in 2014 and identifies common trends occurring across plans. The Digest is available to those who request a copy at http://www.specialtydigest.emdserono.com.
EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology
PR Newswire - Wed Apr 01, 8:30AM CDT
EMD Serono, the U.S. biopharmaceuticals subsidiary of Merck KGaA, Darmstadt, Germany, announced today the appointment of Frederick E. Munschauer to Vice President of Medical Affairs, Neurology and Immunology. In this capacity, he will lead the medical affairs activities for clinical, commercial and business development projects and collaborations for Rebif® (interferon beta-1a) as well as the company's Immunology and Neurology pipeline.
Movado and CBRE Group are big market movers
AP - Tue Mar 31, 3:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
CTRX: 59.61 (+0.30), FBHS: 46.14 (+0.15), DUK: 77.84 (+0.83), CHTR: 191.81 (+0.88), UNH: 119.00 (+0.45), KRFT: 89.27 (-0.13), ASPX: 100.58 (+0.10), CCT.TO: 75.01 (+0.37), OFIX: 37.32 (-0.39), HPTX: 45.79 (-0.01), TCK: 13.75 (-0.21), DYN: 31.31 (+0.46), MOV: 31.37 (-0.25), JCI: 50.09 (-0.46)
Why Shares Intrexon Corp are Skyrocketing Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 30, 11:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Intrexon Corp surged higher...
ZIOP: 10.13 (+0.43), XON: 42.89 (+0.87)
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
GlobeNewswire - Mon Mar 30, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM.
ZIOP: 10.13 (+0.43), MRK: 57.25 (-0.18), XON: 42.89 (+0.87)
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
PR Newswire - Mon Mar 30, 7:00AM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
MRK: 57.25 (-0.18), XON: 42.89 (+0.87)
The Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany, and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy
PR Newswire - Mon Mar 30, 7:00AM CDT
The biopharmaceutical business of Merck KGaA, Darmstadt, Germany, and Intrexon Corporation (NYSE:XON), today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances the comprehensive, science-driven strategy of Merck KGaA, Darmstadt, Germany, to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
XON: 42.89 (+0.87)
Is This Tiny Biotech Still a Buy at All-Time Highs?
Maxx Chatsko, The Motley Fool - Motley Fool - Fri Mar 27, 6:58AM CDT
Does a soaring stock price mean investors should stay away or jump on the bandwagon? Well, it depends. Investors need to consider a multitude of factors, including financial metrics, growth rates, market opportunities, management style, competitive...
RGEN: 30.50 (+0.15), GE: 28.51 (+2.78), MRK: 57.25 (-0.18)
PharmaPoint: Global Colorectal Cancer Drug Forecast and Market Analysis to 2023
M2 - Mon Mar 23, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/blc46f/pharmapoint) has announced the addition of the "PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023" report to their offering. China's Colorectal Cancer Treatment Market Value to Exceed $1 Billion by 2023 This report provides annualized colorectal cancer therapeutics market revenue, cost of therapy, and treatment usage patterns across eight major markets, namely the US, France, Germany, Italy, Spain, UK, Japan and China, from 2013 and forecast to 2023. Key topics covered include pipeline analysis, strategic competitor assessment, unmet needs, remaining commercial opportunities, and current and future players. The Chinese treatment market for colorectal cancer (CRC) will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 15.1%, according to research and consulting firm The authors. The report states that this increase, which will make China the third largest global market for CRC treatment behind the US and Japan, will be driven by increasing disease incidence in urban populations, rising numbers of people covered by private health insurance and improved access to branded biologicals. However, Fenix Leung, DPhil, The authors's Analyst covering Oncology and Hematology, says that growth will be stymied by the patent expiration of Avastin, the leading drug in the Chinese CRC treatment market, and the slower uptake of pipeline therapies. Leung explains: There is often a delay in new drug launches in China relative to the US, Europe and Japan, due to an extended approval process by the China Food and Drug Administration (CFDA). For drugs that have not undergone clinical trials in Chinese patients prior to their application submission, the CFDA can require additional safety studies to be conducted in China before accepting a registration application. As nintedanib, Cyramza, and Imprime PGG are examples of pipeline products that have not undergone clinical trials in China, we do not expect them to launch in this market during the forecast period. Despite this, the report predicts the market entry of four additional drugs by 2023. These include Amgen/Takeda's Vectibix, Bayer's Stivarga, Sanofi's Zaltrap, and Taiho Pharmaceutical's Lonsurf. Leung continues: These agents will garner combined revenues of $334 million in 2023, representing 32% of the Chinese CRC treatment market. Stivarga is expected to be the clear market leader of these drugs, with peak-year sales of $291 million expected in 2023. This will follow its label extension as an adjuvant treatment for CRC patients with resected liver metastases and prior chemotherapy neoadjuvant/adjuvant treatment, the analyst concludes. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Clinical Staging 3.3 Symptoms 4 Epidemiology 4.1 Disease Background 4.2 Risk Factors and Comorbidities 4.3 Global Trends 4.3.1 8MM, Incidence Trends 4.3.2 8MM, Five-Year Relative Survival 4.3.3 8MM, Screening Programs for CRC 4.4 Forecast Methodology 4.4.1 Sources Used 4.4.2 Sources Not Used 4.4.3 Forecast Assumptions and Methods 4.5 Epidemiological Forecast of CRC (2013-2023) 4.5.1 Diagnosed Incident Cases of CRC 4.5.2 Age-Specific Diagnosed Incident Cases of CRC 4.5.3 Sex-Specific Diagnosed Incident Cases of CRC 4.5.4 Age-Standardized Incidence 4.5.5 Cancer Stage at Diagnosis 4.5.6 Diagnosed Five-Year Prevalent Cases of CRC 4.5.7 KRAS Status among Diagnosed Five-Year Prevalent Cases of CRC 4.6 Discussion 4.6.1 Epidemiological Forecast Insight 4.6.2 Limitations of the Analysis 4.6.3 Strengths of the Analysis 5 Disease Management 5.1 Diagnosis and Treatment Overview 5.1.1 Screening and Diagnosis 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 5.1.3 Clinical Practice 6 Competitive Assessment 6.1 Overview 6.2 Product Profiles Major Brands 6.2.1 Avastin (Bevacizumab) 6.2.2 Erbitux (Cetuximab) 6.2.3 Vectibix (Panitumumab) 6.2.4 Stivarga (Regorafenib) 6.2.5 Zaltrap (Ziv-Aflibrcept) 6.2.6 Lonsurf (TAS-102) 6.2.7 TS-1 (Tegafur, Gimeracil, Oteracil) 6.2.8 Xeloda (Capecitabine) 7 Unmet Need and Opportunity 7.1 Overview 7.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients 7.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients 7.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 7.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients 8 Pipeline Assessment 8.1 Overview 8.2 Promising Drugs in Clinical Development 8.2.1 Cyramza (Ramucirumab) 8.2.2 Imprime PGG 8.2.3 MGN1703 8.2.4 Nintedanib (BIBF-1120) 8.3 Promising Approaches in Early-Stage Development 8.3.1 Anti-Angiopoietin-2 Inhibitors 8.3.2 Strategies for BRAF Mutation-Positive Disease 8.3.3 Strategies for KRAS-Mutation Positive Disease 8.3.4 Immune Checkpoint Inhibitors 9 Current and Future Players 9.1 Overview 9.2 Trends in Corporate Strategy 9.3 Company Profiles 10 Market Outlook 11 Appendix Companies Mentioned - Roche/Genentech - Sanofi - Eli Lilly and Company - Merck KGaA - Bayer - Taiho Pharmaceutical For more information visit http://www.researchandmarkets.com/research/bl...harmapoint
LLY: 73.92 (+1.56)
Merck: Why Is Sigma-Aldrich's Deal With Roche Positive For Investors?
BB Research - at Seeking Alpha - Thu Mar 19, 2:50PM CDT
SIAL: 138.45 (-0.09)
Atherosclerosis Partnering 2010-2015: Deals and agreements entered into by the world's leading healthcare companies
M2 - Thu Mar 19, 10:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z43mj9/atherosclerosis) has announced the addition of the "Atherosclerosis Partnering 2010-2015" report to their offering. The Atherosclerosis Partnering 2010-2015 provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of atherosclerosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors atherosclerosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This data driven report contains over 35 links to online copies of actual atherosclerosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In Atherosclerosis Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in atherosclerosis partnering Chapter 3 - Average deal terms for atherosclerosis Chapter 4 - Active atherosclerosis dealmakers Chapter 5 - Atherosclerosis dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/z4...osclerosis
JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), BIIB: 425.65 (-0.98), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Arrhythmia Partnering 2010-2015: Deals and agreements entered into by the worlds leading healthcare companies
M2 - Thu Mar 19, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3wj9g/arrhythmia) has announced the addition of the "Arrhythmia Partnering 2010-2015" report to their offering. The Arrhythmia Partnering 2010-2015 provides understanding and access to the arrhythmia partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of arrhythmia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors arrhythmia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This data driven report contains over 35 links to online copies of actual arrhythmia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In Arrhythmia Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in arrhythmia partnering Chapter 3 - Average deal terms for arrhythmia Chapter 4 - Active arrhythmia dealmakers Chapter 5 - Arrhythmia dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/z3wj9g/arrhythmia
JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), BIIB: 425.65 (-0.98), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Coronary Artery Disease Partnering 2010-2015: Deals and agreements entered into by the world's leading healthcare companies
M2 - Thu Mar 19, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kpf4dh/coronary_artery) has announced the addition of the "Coronary Artery Disease Partnering 2010-2015" report to their offering. The Coronary Artery Disease Partnering 2010-2015 provides understanding and access to the coronary artery disease partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of coronary artery disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors coronary artery disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This data driven report contains over 60 links to online copies of actual coronary artery disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In Coronary artery disease Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in coronary artery disease partnering Chapter 3 - Average deal terms for coronary artery disease Chapter 4 - Active coronary artery disease dealmakers Chapter 5 - Coronary artery disease dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/kp...ary_artery
JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), BIIB: 425.65 (-0.98), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Liver Cancer Partnering Deals and Agreements 2010-2015 - Analysis from the World's Leading Healthcare Companies
M2 - Thu Mar 19, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8sxzpx/liver_cancer) has announced the addition of the "Liver Cancer Partnering 2010-2015" report to their offering. The Liver Cancer Partnering 2010-2015 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report includes: - Trends in Liver cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 livercancer deals and contract documents where available - The leading Liver cancer deals by value since 2010 In Liver Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Liver cancer partnering Chapter 3 - Average deal terms for Liver cancer Chapter 4 - Active Liver cancer dealmakers Chapter 5 - Liver cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/8s...ver_cancer
AGN: 240.22 (+2.88), JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
Gastric Cancer Partnering Deals and Agreements Analysis 2010-2015
M2 - Thu Mar 19, 7:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gc9gpc/gastric_cancer) has announced the addition of the "Gastric Cancer Partnering 2010-2015" report to their offering. The Gastric Cancer Partnering 2010-2015 provides understanding and access to the gastric cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of gastric cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gastric cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 40 links to online copies of actual gastric cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in gastric cancer dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 40 gastric cancer deals and contract documents where available - The leading gastric cancer deals by value since 2010 In Gastric Cancer Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in Gastric cancer partnering Chapter 3 - Average deal terms for Gastric cancer Chapter 4 - Active Gastric cancer dealmakers Chapter 5 - Gastric cancer dealmaking directory Chapter 6 - Partnering resource center Companies Mentioned - Abbott - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/gc...ric_cancer
AGN: 240.22 (+2.88), JNJ: 102.06 (+0.73), ENDP: 94.46 (+0.78), NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), BAX: 70.57 (+0.42), MRK: 57.25 (-0.18), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18), NVS: 103.58 (+1.01)
